Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (20695)	4/16/1999 3:28:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

FWIW, Sorry guys but don't be surprised if we end up closing at 5. You know the law of maximum pain on options where anybody who spent $$ on options gave their $$ to the market makers. Just got to love that NASDAQ market!

To: VLAD who wrote (20695)	4/17/1999 3:32:00 AM
From: AlienTech	Respond to of 23519

APR 16, 1999, M2 Communications - MOUNTAIN VIEW CA -- VIVUS, Inc. (Nasdaq: VVUS) today announced that the abstract "Does Renewed Sexual Activity Increase Cardiac Morbidity? A Meta-Analysis of the Safety Profile with Transurethral Alprostadil (MUSE)" was selected by the XIVth Congress of the European Association of Urology for highlight during a press conference on April 10, 1999 in Stockholm, Sweden. The abstract was presented by co-author Gordon Williams, MD, Consultant Urologist at the Hammersmith Hospital, London. "Although many of the patients in the MUSE studies were already at risk for cardiac events given their history of vascular disease, resuming sexual relations with the use of MUSE did not increase the risk. This study has clearly shown that restoring sexual activity with MUSE does not increase cardiac morbidity or mortality. In fact, several published studies have shown that sexual intercourse is good for you and reduces the risk of a heart attack," commented Dr. Williams. "Safety issues associated with treatment of erectile dysfunction, need to be addressed separately for each of the available treatments." Dr. Williams reported results of multinational studies that enrolled 1,156 patients suffering from severe, organic erectile dysfunction (ED) for an average of four years. No participants had the ability to experience sexual intercourse for at least three months prior to entering the study. Vascular disease or diabetes was present in more than half of the patients. The clinical trials were double-blind, placebo-controlled with half the patients treated with MUSE and the remaining patients receiving placebo. Over the three-month treatment period, patients treated with MUSE had over five times as many occurrences of sexual intercourse but only half as many cardiac events as patients on placebo. Since the approval of the product in November 1996, over 1.2 million prescriptions for MUSE have been filled. Post-approval safety reporting and surveillance have identified only one death reported to the FDA associated with the use of MUSE as the patient's sole ED therapy. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as MUSE (alprostadil). This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacological agents via the urethra. MUSE is not for men with sickle cell trait, disease, or other blood disorders. One third of men reported genital pain, causing some to stop use. A few men reported dizziness and, less commonly, fainting. Note to editors: MUSE is a registered trademark of VIVUS, Inc. Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). beta.iqc.com